Therefore, ATG5 has potential as a significant independent prognostic marker in HNSCC and NPC, and ATG5 is an important target in HNSCC and NPC treatment of ferroptosis, immunotherapy and G2M checkpoint inhibitor. The gene discussed is ATG5; the disease is head and neck squamous cell carcinoma.